Sanofi (NASDAQ:SNY) is a global healthcare company headquartered in Paris, France. It specializes in medical treatments for ...

which the company plans to separate through the creation of a publicly-listed entity headquartered in Paris to be called Opella. Sanofi is conducting exclusive negotiations with CD&R, a U.S.-based ...

Sanofi has launched a new initiative in its drive to integrate digital technologies throughout its business, setting up an accelerator based in Paris that will serve as the lynchpin of the effort.

Management is trying to decide further details such as whether to list the separated business on the Euronext Paris stock exchange. Sanofi’s leaders have also not yet decided what will go into ...

Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...

PARIS – L’Oréal has agreed to sell about 29.6 million Sanofi shares to Sanofi for approximately 3 billion euros. The transaction is to be priced at 101.50 euros per share, the French beauty ...

Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...

L'Oréal was selling 29,556,650 shares at €101.50 each, meaning its stake in Sanofi will decrease from 9.4% to 7.2%. Both listed in Paris, L'Oréal opened 2.5% lower on 3 February following the ...

Sanofi and CD&R sign Opella share purchase agreement Paris, February 19, 2025. Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed ...

N.Y. and PARIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for ...

Sanofi (NASDAQ:SNY) is a global healthcare company headquartered in Paris, France. It specializes in medical treatments for neurology, immunology, oncology, rare diseases, diabetes, and ...